Why the first year can be misleading

A common concern among patients who have had microfracture is why their knee — which felt genuinely better at the one-year mark — begins to ache and stiffen again around the two- or three-year point. The short answer is that early improvement and durable repair are not the same thing, and the tissue that forms after microfracture is often not built to last under everyday joint loading.

At 12 months, both microfracture and injectable collagen scaffold approaches such as ChondroFiller injection can produce meaningful gains: pain frequently decreases, and many patients return to light activity. This convergence is real, but it is partly driven by post-operative inflammation settling and by the initial filling of the defect, rather than by the quality of the tissue that has grown. Standardised clinical scores — Lysholm, KOOS, MOCART — tend to look comparable between the two approaches at this stage.

The divergence becomes apparent in the years that follow. A five-year randomised trial found that MOCART scores (measuring cartilage fill and integration on MRI) had separated to 62.3 versus 26.7 in favour of the hyaline-producing group, and functional scores widened similarly. Crucially, arthroscopic studies show that cartilage tissue quality differs between groups before patients themselves notice any clinical decline — meaning the biological problem is already developing while symptoms still feel acceptable.

The 2–3 year window is when cumulative mechanical loading begins to test repair tissue in earnest. What determines whether it holds is examined in the sections that follow.

What microfracture actually grows inside the defect

The perforations that microfracture creates in subchondral bone serve a deliberate purpose: they open channels into the bone marrow, releasing mesenchymal stem cells (BMSCs) — cells with the potential, in the right conditions, to produce cartilage tissue. That recruitment step works. The problem lies in what happens next.

Without a structural matrix to guide them, the recruited BMSCs settle into a fibrin clot at the base of the defect and take the path of least resistance. They differentiate into fibrocartilage — dominated by Type I collagen rather than the Type II collagen and high aggrecan content of native hyaline cartilage. The mechanical difference matters: hyaline cartilage has a layered, zone-by-zone collagen architecture interlocked with a dense proteoglycan–water matrix, allowing it to absorb and distribute the cyclic loads of walking, running, and stair-climbing. Fibrocartilage has neither the architecture nor the proteoglycan density to perform that work sustainably.

At 12 months, the defect appears filled and imaging may look reassuring. Filling a structural gap with the wrong material covers it initially; under sustained load, the mismatch tells. Over the following years, the mechanically weaker repair tissue begins to fragment — which is the biological mechanism behind the midterm clinical decline that microfracture literature consistently documents, and whose trajectory was already outlined above.

That deterioration is not, however, a biologically inevitable consequence of the procedure. It is an environment-dependent outcome. Studies confirm that when BMSCs are provided with a three-dimensional scaffold — one that retains them at the repair site and sustains the microenvironmental signals for chondrogenesis — the same recruited cells can be directed toward hyaline-like tissue rather than fibrocartilage. The cell-recruitment principle of microfracture is sound; what it lacks is the guiding matrix. That absence is precisely the failure point that injectable collagen scaffold approaches such as ChondroFiller injection are designed to address.

The subchondral bone problem microfracture leaves behind

Beneath the repair tissue lies a second problem that microfracture can create — and one that compound its effects over time.

The perforations needed to release bone marrow cells also breach the subchondral plate: the dense, load-bearing bone layer that sits immediately beneath cartilage and acts as its structural foundation. In some patients this disruption resolves without complication. In others it can trigger reactive changes — localised cystic cavities or areas of sclerosis (bone hardening) that leave the surface beneath the repair irregular and biomechanically compromised. An uneven platform is a poor base for any repair tissue to rest on, regardless of its quality; the combination of fragile fibrocartilage above and altered bone below accelerates structural deterioration.

This also matters for future options. A subchondral layer that has undergone cystic or sclerotic change is more technically challenging to treat, and outcomes of any subsequent cartilage restoration procedure are less predictable.

Patient age adds a further layer. Bone marrow mesenchymal stem cells lose their capacity to differentiate towards cartilage as a person ages, and age of 50 or above at the time of surgery has been identified as an independent negative predictor of microfracture outcome. Timing a specialist assessment earlier — before both the subchondral foundation and the available cell pool are compromised — is therefore clinically meaningful.

How an injectable collagen scaffold changes the repair environment

The mechanism answer to that absent matrix is what ChondroFiller injection is designed to supply.

Delivered as an ultrasound-guided outpatient injectable collagen scaffold — no theatre, no general anaesthetic — ChondroFiller is placed directly into the cartilage defect, where it gels in situ to form a three-dimensional scaffold within the space. Because it is acellular, there are no donor cells to harvest or culture: the patient's own progenitor cells, already recruited to the site from subchondral bone marrow, do the biological work. The scaffold's micropore architecture and endogenous extracellular matrix factors retain those cells within the defect and provide the physical and biochemical environment that microfracture alone cannot.

The critical biological shift is in what those retained cells are directed to become. Research into scaffold-augmented marrow stimulation confirms that sustained provision of chondrogenic signals — including upregulation of SOX9, a master regulator of cartilage cell differentiation — can redirect BMSCs away from the fibrocartilage default and toward hyaline-like repair tissue. SOX9 activity drives Type II collagen and proteoglycan production: the constituents that give native cartilage its load-bearing architecture. The fibrocartilage outcome is not hardwired into the cell; it is a consequence of a missing signal that the scaffold can restore.

Preclinical evidence supports this mechanism directly. In an ovine model, a collagen scaffold combined with an adhesive hyaluronan-based hydrogel supported mesenchymal cell migration from subchondral bone, chondrogenic differentiation within the defect, and meaningfully better preservation of the adjacent cartilage compared with untreated defects — a guided biological process with a substantially different tissue trajectory.

What the clinical evidence shows — and where the gaps are

The comparative evidence breaks into two distinct layers, and reading them accurately matters.

The strongest available data come from randomised controlled trials comparing scaffold-based or hyaline-producing repair to microfracture. A prospective five-year RCT of costal chondrocyte ACI versus microfracture found marked divergence by year five despite broadly comparable early improvement in both groups: MOCART scores were 62.3 versus 26.7, Lysholm scores 84.5 versus 64.9, and KOOS totals 390.9 versus 303.0. A 12-month multicenter RCT of a biphasic scaffold implant (BiCRI) versus microfracture reached a similar conclusion from a different angle: functional scores (IKDC) were non-inferior at 12 months, yet arthroscopic examination showed more fully regenerated cartilage in the scaffold group — confirming that tissue quality diverges before clinical scores do. Multiple systematic reviews reinforce this pattern: early functional equivalence, followed by midterm fibrocartilage deterioration, is a consistent feature of microfracture outcomes in the published literature.

These trials are the best available proxy for understanding the scaffold-versus-microfracture mechanism, but they are not ChondroFiller trials. Direct head-to-head randomised data comparing ChondroFiller injection to standalone microfracture, with histological endpoints at two to three years, has not yet been published. The mechanistic rationale for scaffold-guided chondrogenesis is well-supported by preclinical and comparative evidence; product-specific long-term RCT confirmation remains the outstanding requirement.

From clinical and registry data, ChondroFiller injection is associated with IKDC improvements of approximately 30 points in the knee, comparable mHHS gains in the hip, MOCART scores in the range of 70 to 87, and a recorded complaint rate of around 0.06%.

Who is most affected and when assessment matters

Three patient groups emerge from the evidence as carrying the highest risk of the midterm decline described above: those who have already had microfracture at the same site, those presenting with defects above 2 cm², and patients over 50, whose reduced BMSC regenerative capacity — already established in earlier sections — compounds each of the tissue-quality problems outlined above. For these patients in particular, the timing of assessment is not a minor administrative detail.

The critical window opens before fibrocartilage begins to fragment and before subchondral cystic or sclerotic changes become established — both of which progressively narrow future options. Waiting for a marked return of mechanical symptoms before seeking review means that some of the most effective pathways may already be foreclosed by then.

For suitable focal defects identified at that point, the ChondroFiller injection pathway offers a single-stage, ultrasound-guided outpatient route that directly addresses the scaffold-absence failure mode, without the theatre demands of MACI or two-stage ACI. Where surgery is indicated for other clinical reasons, AMIC — matrix-augmented microfracture, in which a collagen membrane is placed over the perforation sites during the same operative step — provides a surgical middle ground that partially addresses the same mechanism.

Establishing defect size and grade, subchondral bone integrity, and overall lower-limb alignment requires a formal cartilage specialist assessment — and that assessment is the essential first step before any repair pathway can be appropriately matched to the individual.

1. [1] Injectable acellular matrix microgel assembly with stem cell recruitment and chondrogenic differentiation functions promotes microfracture-based articular cartilage regeneration. (2024). https://doi.org/10.1016/j.bioactmat.2024.10.013 https://doi.org/10.1016/j.bioactmat.2024.10.013
2. [2] Combination of a Collagen Scaffold and an Adhesive Hyaluronan-Based Hydrogel for Cartilage Regeneration: A Proof of Concept in an Ovine Model. (2021). https://doi.org/10.1177/1947603521989417 https://doi.org/10.1177/1947603521989417
3. [3] Biphasic cartilage repair implant versus microfracture in the treatment of focal chondral and osteochondral lesions of the knee: a prospective, multi-center, randomized clinical trial. (2024). https://doi.org/10.1186/s10195-024-00802-1 https://doi.org/10.1186/s10195-024-00802-1
4. [4] Microfracture and Microfracture Plus of the Knee Joint. (2024). https://doi.org/10.1016/j.csm.2024.10.003 https://doi.org/10.1016/j.csm.2024.10.003
5. [5] Enhancing Cartilage Repair: Surgical Approaches, Orthobiologics, and the Promise of Exosomes. (2024). https://doi.org/10.3390/life14091149 https://doi.org/10.3390/life14091149
6. [6] Long-Term Outcomes of Autologous Osteochondral Transfer of the Knee Are Successful and Predicated Upon Appropriate Patient Selection. (2024). https://doi.org/10.1016/j.arthro.2024.03.012 https://doi.org/10.1016/j.arthro.2024.03.012
7. [7] Costal Chondrocyte–Derived Pellet-Type Autologous Chondrocyte Implantation Versus Microfracture for the Treatment of Articular Cartilage Defects: A 5-Year Follow-up of a Prospective Randomized Trial. (2024). https://doi.org/10.1177/03635465231222797 https://doi.org/10.1177/03635465231222797
8. [8] Long-term Outcomes of Microfracture for Treatment of Osteochondral Lesions of the Talus. (2021). https://doi.org/10.1177/1071100721995427 https://doi.org/10.1177/1071100721995427
9. [9] Response to 'Letter Regarding: Long-term Outcomes of Microfracture for Treatment of Osteochondral Lesions of the Talus'. (2022). https://doi.org/10.1177/10711007211058694 https://doi.org/10.1177/10711007211058694
10. [10] Comparison of 5 BMPs for their chondrogenic potentials and microfracture-mediated cartilage repair using heparin/PEAD coacervate sustained release polymer. (2025). https://doi.org/10.1016/j.bioactmat.2025.06.031 https://doi.org/10.1016/j.bioactmat.2025.06.031
11. [11] Hyaline cartilage. https://en.wikipedia.org/wiki/Hyaline_cartilage https://en.wikipedia.org/wiki/Hyaline_cartilage
12. [12] Microfracture surgery. https://en.wikipedia.org/wiki/Microfracture_surgery https://en.wikipedia.org/wiki/Microfracture_surgery
13. [13] SPI1 facilitates microfracture-mediated cartilage regeneration in the elderly by enhancing bone marrow stromal cells stemness. (2025). https://doi.org/10.1177/20417314241311073 https://doi.org/10.1177/20417314241311073
14. [14] Articular cartilage repair. https://en.wikipedia.org/wiki/Articular_cartilage_repair https://en.wikipedia.org/wiki/Articular_cartilage_repair